AS-Patisiran (sodium)
Product Specifications
UNSPSC Description
AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis[1][2][3].
Target Antigen
Small Interfering RNA (siRNA); Transthyretin (TTR)
Type
Oligonucleotides
Related Pathways
Epigenetics;Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/as-patisiran.html
Solubility
H2O : ≥ 100 mg/mL
Smiles
[AS-Patisiran (sodium)]
Molecular Weight
6661.30
References & Citations
[1]Adams D, et, al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21.|[2]Hoy SM. Patisiran: First Global Approval. Drugs. 2018 Oct;78(15):1625-1631.|[3]Kristen AV, et, al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019 Feb;9(1):5-23.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153609/AS-Patisiran-sodium-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153609/AS-Patisiran-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RC201308L3V 200 µL
MMTAG2 (C1orf35) (NM_024319) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details 
